Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on precision medicines for oncology and genetically defined conditions. Its pipeline centers on oral small-molecule programs that target fibroblast growth factor receptor (FGFR) biology, including dabogratinib and TYRA-200, supported by its proprietary SNÅP drug-design platform.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaOral small-molecule programs in clinical development for FGFR-driven cancers and related conditions.
SNÅP is the internal drug-design platform used to generate and optimize new candidates.
Undisclosed early-stage programs focused on FGFR biology and other precision-oncology targets.
Asiakkaat
Tyra Biosciences does not currently sell commercial products; its near-term 'customers' are clinical trial participants, investigators, and research sites that support development of its drug candidates. If approved in the future, its products would be used by oncology and specialty-care physicians treating FGFR-driven cancers and genetic conditions.
Patients with FGFR-altered cancers or genetic conditions enrolled in studies of TYRA-200, TYRA-430, and dabogratinib.
Hospitals and research centers that recruit patients, administer study drugs, and generate safety/efficacy data.
Oncologists who would prescribe approved FGFR-targeted therapies for urothelial cancer, ICC, HCC, and other tumors.
Physicians treating skeletal dysplasia who could use dabogratinib if it reaches that indication.
Strategia
Tyra Biosciences is building a wholly owned pipeline around FGFR biology, using its SNÅP platform to design more selective oral candidates with the goal of improving potency, tolerability, and resistance coverage. Its strategy is to advance lead programs in FGFR3- and FGFR4-related disease settings while extending the platform into additional precision-oncology targets.
Clinical proof-of-concept is the main value driver for a pre-revenue biotech.
Better selectivity and resistance handling can improve efficacy and tolerability versus older FGFR drugs.
A productive platform can create multiple shots on goal beyond the current pipeline.
Maantiede
Tyra Biosciences is headquartered in the United States and conducts development work through a clinical-trial network that can span multiple countries. Its business is geographically driven by where patients can be enrolled, where regulators approve trials, and where future commercialization partners may operate.
Riskit
Tyra Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and the possibility that its candidates never reach commercialization. It also depends on third-party manufacturers and clinical infrastructure, which creates supply-chain, execution, and geopolitical exposure, including potential reliance on China-based contract manufacturers.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
The company has no approved products, so value depends on positive trial readouts and tolerability.
Kohdistuu - Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even promising data may not translate into marketing approval or label breadth.
Kohdistuu: all pipeline programs
- Competitive displacementVaikutus: KorkeaTodennäköisyys: Kohtalainen
Other FGFR and oncology therapies may be more effective, safer, or faster to market.
Kohdistuu: FGFR-targeted oncology
- Third-party manufacturing and CRO dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company relies on external partners for clinical supply and trial execution.
Kohdistuu: clinical and preclinical programs
- China sourcing and trade restrictionsVaikutus: Keskitaso
Use of foreign contract manufacturers can be affected by tariffs, sanctions, and U.S. restrictions.
Kohdistuu: manufacturing supply chain
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical vendor costs must be estimated when invoices lag activity.
Vaikutus: Can move quarterly operating expense and liabilities
Equity awards are common in development-stage biotech and can be material.
Vaikutus: Affects operating loss and equity dilution
Cash preservation and investment returns matter for a pre-revenue company.
Vaikutus: Affects other income and liquidity presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Damora Therapeutics, Inc.
DMRA · Pharmaceutical Preparations
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Forte Biosciences, Inc.
Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Päivitetty: 24.9.2026